SK bioscience shares extend gains on expectations for Bill Gates meeting

Pulse 입력 2022. 8. 12. 14:18
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Source: SK bioscience]
SK bioscience shares extended gains Friday on reports that Bill & Melinda Gates Foundation co-chair Bill Gates was to meet the management of the Korean vaccine maker, timed with the domestic shipment of Korea’s first Covid-19 vaccine.

SK bioscience shares were 2.4 percent higher at 129.500 won ($100) after going as high as 133,000 won following the rise of 4.6 percent on the previous session.

A local media reported Bill Gates will have a meeting with the South Korean vaccine manufacturer to discuss Covid-19 vaccine production and distribution.

SK bioscience developed SKYCovione, the country’s first homegrown Covid-19 vaccine, which was approved by local health authorities in June. The company received 4.4 billion won funding from Bill & Melinda Gates Foundation for vaccine development.

The meeting has raised expectations for a push for global marketing of the Korean vaccine.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지

이 기사에 대해 어떻게 생각하시나요?